Brief: Shanghai Junshi Biosciences Says Js207 Injection Received Acceptance Notice For IND Application
19/06/2023 13:18
June 19 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* SHANGHAI JUNSHI BIOSCIENCES - JS207 INJECTION RECEIVED
ACCEPTANCE NOTICE FOR INVESTIGATIONAL NEW DRUG APPLICATION
* SHANGHAI JUNSHI BIOSCIENCES - JS207 IS WELL TOLERATED BY
ANIMALS
* SHANGHAI JUNSHI BIOSCIENCES - PRECLINICAL IN VIVO EFFICACY
TRIALS HAVE SHOWN JS207 HAS SIGNIFICANT ANTI-TUMOR EFFECT
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab